hsieh-banner1

Publications

Peer reviewed publications, reviews and book chapters

2019 | 2018 2017 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2004

2019 

Liu Y*, Horn JL*, Banda K*,  Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC. (2019). Androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Science Translational Medicine doi: 10.1126/scitranslmed.aaw4993 *co-first authors

Kuppers DA, Arora S, Lim Y, Lim A, Carter L, Corrin P, Plasier CL, Basom R, Delrow J, Wang S, He HH, Torok-Storb B, Hsieh AC*, Paddison PJ*. (2019). N6-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis. Nature Communications doi: 10.1038/s41467-019-12518-6 *co-corresponding author

Schuster SL, Hsieh AC. (2019). The untranslated regions of mRNAs in cancer. Trends in Cancer doi: 10.1016/j.trecan.2019.02.011

Winters BR*, De Sakar N*, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas, P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL#, Lam H#, Hsieh AC#. (2019). Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight doi: 10.1172/jci.insight.128728 *co-first authors #co-corresponding author

Labrecque, MP, Coleman IM, Brown LG, True LD, Kollath J, Lakely B, Nguyen HM, Yang YC, Kaipainen AH, Coleman RT, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery RB, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. (2019). Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. JCI. doi.org/10.1172/JCI128212

file

Schweizer M, Antonarakis E, Bismar T, Guedes L, Cheng HH, Tretiakova M, Vakar-Lopez F, Klemfuss N, Konnick E, Mostaghel E, Hsieh AC, Nelson PS, Yu E, Montgomery B, True L, Epstein J, Lotan T, Pritchard C. (2019). Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precision Oncology doi: 10.1200/PO.18.00327

2018 

Graham L, Banda K, Pisano, K, Shelley G, Curley T, Scher HI, Lotan TL, Hsieh AC*, Rathkopf DE*. (2018).  A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer. (2018). Investigational New Drugs doi: 10.1007/s10637-018-0578-9 *co-corresponding author

Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang J, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. (2018). Development of a stress response therapy targeting aggressive prostate cancer. Science Translational Medicine doi: 10.1126/scitranslmed.aar2036

Winters BR, Vakar-Lopez F, Brown L, Montgomery RB, Seiler R, Black P, Boormans JL, Dall'Era M, Davincioni E, Douglas J, Gibb E, Van Rhijn BWG, Van der Heijden M, Hsieh AC, Wright JL, Lam H. (2018) Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urologic Oncology: Seminars and Original Investigations doi: 10.1016/j.urolonc.2018.03.016

2017 

Jana S, Hsieh AC, Gupta R. (2017). Reciprocal amplification of caspase-3 activity by nuclear export of a putative human RNA-modifying protein, PUS10 during TRAIL-induced apoptosis. Cell Death & Disease doi: 10.1038/cddis.2017.476

Wei XX, Hsieh AC, Kim W, Friedlander TW, Lin AM, Louttit M, Ryan CJ. (2017). A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer. The Oncologist doi: 10.1634/theoncologist.2016-0432

2015

Hsieh AC*, Nguyen HG, Wen L, Edlind MP, Carroll P, Kim W, Ruggero D.* (2015). Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Science Signaling doi: 10.1126/scisignal.aad5111 *co-corresponding author

Sheridan CM, Grogan T, Nguyen HG, Rettig M*, Hsieh AC*, Ruggero D.*  (2015). YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence. Oncotarget doi: 10.18632/oncotarget.3477  *co-corresponding author

 

Publications prior to joining Fred Hutch

file

2014

Edlind MP, Hsieh AC. (2014). PI3K-AKT-mTOR signalling in prostate cancer progression and androgen deprivation therapy resistance. Asian Journal of Andrology doi: 10.4103/1008-682X.122876

Long-Cheng L, Hsieh AC, Ruggero D, Greene KL, Carroll PR: Molecular Basis of Prostate Cancer. In: The Molecular Basis of Cancer, 4th Edition. Mendelsohn J, Howley P, Israel M, Gray J, Thompson C. (eds), 2014. doi: 10.1016/B978-1-4557-4066-6.00038-X

2013

Olshen AB, Hsieh AC, Stumpf CR, Olshen RA, Ruggero D, Taylor BS. (2013). Assessing gene-level translational control from ribosome profiling. Bioinformatics doi: 10.1093/bioinformatics/btt533

2012

Hsieh AC*, Liu Y*, Edlind MP, Ingolia, NT, Janes MR, Sher A, Shi EY, Christensen C, Stumpf CR, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. (2012). The translational landscape of mTOR signaling steers cancer initiation and metastasis. Nature doi: 10.1038/nature10912 *co-first author

2011

Hsieh AC, Truitt ML, Ruggero D. (2011). Oncogenic AKTivation of translation as a therapeutic target. British Journal of Cancer doi: 10.1038/bjc.2011.241

Kondrashov N, Pusic A, Stumpf, CR, Shimizu K, Hsieh AC, Ishijima J, Kikkawa Y, Shiroishi T, Barna M. (2011). Ribosome-mediated specificity of Hox mRNA translation and vertebrate tissue patterning. Cell doi: 10.1016/j.cell.2011.03.028

2010

Hsieh AC*, Costa M*, Zollo O, Davis C, Feldman M, Testa JR, Meyuhas O, Shokat K, Ruggero D. (2010). Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell doi: 10.1016/j.ccr.2010.01.021 *co-first author  

Hsieh AC, Ruggero D. (2010). Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in cancer. Clinical Cancer Research doi: 10.1158/1078-0432.CCR-10-0433 

2009

Mawad R, Hsieh AC, Damon L. (2009) Graft-versus-Host Disease presenting with pancytopenia after en-bloc multi-organ transplant: case report and literature review. Transplantation Proceedings doi: 10.1016/j.transproceed.2009.06.229

Cell magazine 2010 cover

2008

Hsieh AC, Ryan CJ. (2008). Novel Concepts in Androgen Receptor Blockade. Cancer Journal doi: 10.1097/PPO.0b013e318161d13e

2007

Hsieh AC, Moasser MM. (2007). Targeting HER proteins in cancer therapy and the role of the non-target HER3. British Journal of Cancer doi: 10.1038/sj.bjc.6603910

Hsieh AC*, Small EJ, Ryan CJ. (2007). Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncology doi: 10/1016/S1470-2045(07)70316-9 *corresponding author 

2004

Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, Scaringe S, Sellers WR. (2004). A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: Determinants of gene silencing for use in cell-based screens. Nucleic Acid Research doi: 10/1093/nar/gkh238